Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
Half of 25 patients with Merkel cell carcinoma treated with pembrolizumab experienced significant tumor shrinkage that lasted almost 3 times longer than conventional chemotherapy, and some had no remaining disease after treatment.
Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.